Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings

AIDS

Volumn 26, Issue 6, 2012, Pages 707-710

  Moss, John A ^a   Baum, Marc M ^a   Malone, Amanda M ^b   Kennedy, Sean ^a   Kopin, Etana ^b   Nguyen, Cali ^a,b   Gilman, Josh ^b   Butkyavichene, Irina ^b   Willis, Robyn A ^b   Vincent, Kathleen L ^c   Motamedi, Massoud ^c   Smith, Thomas J ^a,b,d  

^a OAK CREST INSTITUTE OF SCIENCE   (United States)

^b Auritec Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

intravaginal ring; preexposure prophylaxis; sheep; tenofovir; tenofovir disoproxil fumarate; topical delivery

Indexed keywords

TENOFOVIR; TENOFOVIR DISOPROXIL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; SHEEP; STATISTICAL SIGNIFICANCE; VAGINA RING; VAGINAL LAVAGE;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-HIV AGENTS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; PHOSPHONIC ACIDS; PRODRUGS; SHEEP; VAGINAL DOUCHING;

EID: 84859103724     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283509abb     Document Type: Article

References (15)

1. Mobilization for microbicides: the decisive decade. New York: The Rockefeller Foundation; 2002. http://www.global-campaign. org/clientfiles/ RockExecSumm.pdf. [Accessed 8 September 2011]
2. D'Cruz OJ, Uckun FM. Clinical development ofmicrobicides for the prevention of HIV infection. Curr Pharm Design 2004; 10:315-336. (Pubitemid 38072766)
3. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety oftenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
4. Johnson TJ, Gupta KM, Fabian J, Albright TH, Kiser PF. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 2010; 39:203-212.
5. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances inmicrobicide vaginal rings. Antiviral Res 2010; 88:S30-S39.
6. Moss JA, Malone AM, Smith TJ, Kennedy S, Kopin E, Nguyen C, et al. Simultaneous delivery oftenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother 2011. doi: 10.1128/AAC.05662-11. [Epub ahead of print]
7. Van Gelder J, Deferme S, Naesens L, De Clercq E, van den Mooter G, Kinget R, et al. Intestinal absorption enhancement ofthe ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 2002; 30:924-930. (Pubitemid 34815423)
8. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Antihuman immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42:612-617. (Pubitemid 28114817)
9. Snyder LR, Kirkland JJ, Glajch JL. Practical HPLC method development. 2nd ed. New York: Wiley; 1997.
10. Arimilli MN, Kim CU, Dougherty J, Mulato A, Oliyai R, Shaw JP, et al. Synthesis, invitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antivir Chem Chemother 1997; 8:557-564. (Pubitemid 27504721)
11. Vincent KL, Bourne N, Bell BA, Vargas G, Tan A, Cowan D, et al. High resolution imaging ofepithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex Transm Dis 2009; 36:312-318.
12. Hendrix CW, Cao YJ, Fuchs EJ. Topical microbicides toprevent HIV: clinical drug development challenges. Annu Rev Pharmacol Toxicol 2009; 49:349-375.
13. Karim SSA, Kashuba ADM, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral preexposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378:279-281.
14. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 2011; 66:240-250.
15. McMahon MA, Shen L, Siliciano RF. New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Curr Opin Infect Dis 2009; 22:574-582.